Participation of patients with gynecological cancer in phase I clinical trials: Two years experience in a major cancer center

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 551-556

  Legge, F ^a,b   Eaton, D ^c   Molife, R ^c   Ferrandina, G ^b   Judson, I ^c   de Bono, J ^c   Kaye, S ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Gynecological cancers; Ovarian cancer; Phase I trials; Target based therapies

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; INSULIN LIKE GROWTH FACTOR RECEPTOR INHIBITOR; METHYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DNA REPAIR; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HEPATOBILIARY DISEASE; HUMAN; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PATIENT PARTICIPATION; PATIENT REFERRAL; PATIENT SELECTION; PERFORMANCE; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; VAGINA CANCER;

ADULT; AGED; CLINICAL TRIALS, PHASE I; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PATIENT SELECTION; RESEARCH SUBJECTS; RETROSPECTIVE STUDIES;

EID: 33846924587     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.09.020     Document Type: Article

References (21)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 (1999) 827-841
2. Levi F., Lucchini F., Negri E., and La Vecchia C. Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer 101 12 (2004) 2843-2850
3. Legge F., Ferrandina G., Salutari V., and Scambia G. Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann. Oncol. 16 Suppl. 4 (2005) iv95-iv101
4. Wolf J.K., Franco E.L., Arbeit J.M., Shroyer K.R., Wu T.C., Runowicz C.D., et al. Innovations in understanding the biology of cervical cancer. Cancer 98 9 (2003) 2064-2069
5. Lara Jr. P.N., Higdon R., Lim N., Kwan K., Tanaka M., Lau D.H., et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J. Clin. Oncol. 19 6 (2001) 1728-1733
6. Kinney A.Y., Richards C., Vernon S.W., and Vogel V.G. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. Prev. Med. 27 5 Pt 1 (1998) 713-719
7. Mannel R.S., Walker J.L., Gould N., Scribner Jr. D.R., Kamelle S., Tillmanns T., et al. Impact of individual physicians on enrollment of patients into clinical trials. Am. J. Clin. Oncol. 26 2 (2003) 171-173
8. Luck M.B., McIntire M., Blades N., and Robinson W. Characteristics of women with gynecologic cancer who enter clinical trials. J. Reprod. Med. 50 7 (2005) 481-485
9. Sateren W.B., Trimble E.L., Abrams J., Brawley O., Breen N., Ford L., et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J. Clin. Oncol. 20 8 (2002) 2109-2117
10. Harter P., du Bois A., Schade-Brittinger C., Burges A., Wollschlaeger K., Gropp M., et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann. Oncol. 16 11 (2005) 1801-1805
11. Moore D.H., Kauderer J.T., Bell J., Curtin J.P., and Van Le L. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol. Oncol. 94 2 (2004) 368-374
12. Villella J., and Chalas E. Optimising treatment of elderly patients with ovarian cancer: improving their enrollment in clinical trials. Drugs Aging 22 2 (2005) 95-100
13. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 53 (1958) 457-481
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50 (1966) 163-170
15. Cox D.R. Regression models and life tables. J. R. Stat. Soc 34 (1972) 197-220
16. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 1 (1996) 1-6
17. Peters III W.A., Liu P.Y., Barrett II R.J., Stock R.J., Monk B.J., Berek J.S., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 18 8 (2000) 1606-1613
18. Muggia F., and Kosloff R. Investigational agents for epithelial ovarian cancer. Expert Rev. Anticancer Ther. 5 5 (2005) 855-868
19. Davis S., Wright P.W., Schulman S.F., Hill L.D., Pinkham R.D., Johnson L.P., et al. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 56 7 (1985) 1710-1718
20. Gnant M., and Austrian Breast and Colorectal Cancer Study Group. Impact of participation in randomised clinical trials on survival of women with early stage breast cancer. Proc. Am. Soc. Clin. Oncol. 19 (2000) 74a [Abstract 287]
21. Peppercorn J.M., Weeks J.C., Cook E.F., and Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363 9405 (2004) 263-270